Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-009 plus Paclitaxel in Advanced Biliary Tract Cancers
NCT05506943Phase 3Active, not recruiting
- Sponsor
- Compass Therapeutics, Inc.
- Start
- Jan 2023
- Primary completion
- Aug 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tovecimig in biliary tract cancer (BTC), sponsored by Compass Therapeutics, Inc.. Started Jan 2023; status: active, not recruiting.
02
Drugs
tovecimig
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05506943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05506943.